Arcutis Biotherapeutics (ARQT) Cost of Revenue (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Cost of Revenue of $9.8 million for Q1 2026, up 10.8% year-over-year from $8.8 million in Q1 2025, and down 16.29% quarter-over-quarter from $11.7 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Cost of Revenue (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Cost of Revenue history runs 5 years deep, the most recent figure standing at $9.8 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 10.8% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $37.6 million (up 52.41% YoY), while the FY2025 annual figure was $36.7 million, up 91.84% from the prior year.
- Cost of Revenue for Q1 2026 stood at $9.8 million, down from $11.7 million in the prior quarter.
- The five-year high for Cost of Revenue was $11.7 million in Q4 2025, with the low at $269000.0 in Q3 2022.
- The 5-year median for Cost of Revenue is $3.5 million (2024), against an average of $4.8 million.
- The sharpest annual moves came in 2024 and 2026: Cost of Revenue jumped 365.57% in 2024, then grew 10.8% in 2026.
- Arcutis Biotherapeutics' Cost of Revenue stood at $485000.0 in 2022, then jumped by 363.09% to $2.2 million in 2023, then jumped by 207.44% to $6.9 million in 2024, then jumped by 69.27% to $11.7 million in 2025, then fell by 16.29% to $9.8 million in 2026.
- Business Quant data shows ARQT's Cost of Revenue at $9.8 million in Q1 2026, $11.7 million in Q4 2025, and $8.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 10.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.94 Mn |
| Jun 30, 2026 | 10.94 Mn |
| Mar 31, 2026 | 9.78 Mn |
| Mar 31, 2026 | 9.78 Mn |
| Dec 31, 2025 | 11.69 Mn |
| Dec 31, 2025 | 11.69 Mn |
| Sep 30, 2025 | 8.69 Mn |
| Sep 30, 2025 | 8.69 Mn |
| Jun 30, 2025 | 7.49 Mn |
| Jun 30, 2025 | 7.49 Mn |
| Mar 31, 2025 | 8.83 Mn |
| Mar 31, 2025 | 8.83 Mn |
| Dec 31, 2024 | 6.91 Mn |
| Dec 31, 2024 | 6.91 Mn |
| Sep 30, 2024 | 5.50 Mn |
| Sep 30, 2024 | 5.50 Mn |
| Jun 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 3.46 Mn |
| Mar 31, 2024 | 3.26 Mn |
| Mar 31, 2024 | 3.26 Mn |